No Data
Express News | Guangdong Biolight Meditech: Subsidiary received government grant of 60.43 million yuan
Guangdong Biolight Meditech (300246.SZ): In the first half of the year, the health monitoring sector's revenue was 0.133 billion yuan, accounting for about 25% of total revenue.
On November 19, Gelonghui reported that Guangdong Biolight Meditech (300246.SZ) stated in its investor relations that, taking the first half of 2024 as an example, the sales revenue of the health monitoring sector is 133.3011 million yuan, accounting for approximately 25% of the revenue; the sales revenue of the blood purification sector is 398.564 million yuan, accounting for approximately 74% of the revenue.
Guangdong Biolight Meditech (300246.SZ): The self-developed PD600 peritoneal dialysis equipment has obtained the "Medical Instruments Registration Certificate".
On November 19, Gelonghui reported that Guangdong Biolight Meditech (300246.SZ) announced in their investor relations that the company has been actively laying out the peritoneal dialysis field in recent years. The PD600 peritoneal dialysis device, developed independently by the company, has obtained the "Medical Instruments Registration Certificate". This product has a complete range of treatment modes, is equipped with an Internet of Things system, and can achieve remote monitoring and automated operation through software support. It features an integrated design, is lightweight for convenient home use by patients, and includes practical functions and features such as intelligent voice guidance, video operation guidance, multi-device data collection, and Bluetooth transmission. Additionally, disposable peritoneal dialysis supplies are used in conjunction with the company's peritoneal dialysis equipment.
Guangdong Biolight Meditech (300246.SZ): Export revenue is mainly from medical monitor product income.
Guangdong Biolight Meditech (300246.SZ) stated in the investor relations that in the previous year as an example, the company's export revenue in 2023 was 0.248 billion yuan, accounting for about 21% of the revenue; domestic sales revenue was 0.93 billion yuan, accounting for about 78% of the revenue (data rounded off). The company's export revenue mainly comes from medical monitor product revenue, and the hemodialysis series products also have export business, including overseas sales of blood dialysis equipment, dialyzers, and dialysis fluid filters. Currently, the company's leading export products have all passed EU CE certification, USA FDA 510(k) clearance, USA.
Guangdong Biolight Meditech (300246.SZ): In 2023, the company launched a new series of products including the S series infusion pumps, electronic urine volume meters, telemetry monitoring systems, etc.
On November 19, Gelonghui reported that Guangdong Biolight Meditech (300246.SZ) stated in an investor relations meeting that the company continues to adhere to a high-end route, focusing on the core pain points of patients and doctors. The company concentrates on deeply cultivating the critical care monitoring field and enriching the surgical anesthesia and ICU application solutions, further improving the category and structure of its medical monitor products. The competitiveness of the company's monitoring products is increasingly strengthened, among which high-end medical monitors possess several unique parameters, industry-leading technologies to resolve key issues in surgical anesthesia against electric knife interference, practical additional functions such as equipment management and liquid management, voice interaction capabilities, as well as being equipped with an Internet of Things system for informational visualization, and more.
Guangdong Biolight Meditech (300246.SZ): In the field of blood purification, it has products such as blood dialysis equipment and polyethersulfone membrane blood dialyzers.
Guangdong Biolight Meditech (300246.SZ) stated in investor relations that in the field of blood purification, the company has a complete industry chain layout, including nine major consumables bases, three major channel platforms, a comprehensive product structure. It has products such as hemodialysis equipment (machines), polyethersulfone membrane hemodialyzers, dialysate filters, hemodialysis dry powder/dialysate, disinfectant, dialysis water treatment equipment, peritoneal dialysis equipment and supporting tubing, widely used in the treatment of acute and chronic renal failure.
No Data
